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Abstract
Gliomas such as oligodendrogliomas (ODG) and glioblastomas (GBM) are brain tumours with different clinical outcomes.
Histology-based classification of these tumour types is often difficult. Therefore the first aim of this study was to gain
microRNA data that can be used as reliable signatures of oligodendrogliomas and glioblastomas. We investigated the levels
of 282 microRNAs using membrane-array hybridisation and real-time PCR in ODG, GBM and control brain tissues. In
comparison to these control tissues, 26 deregulated microRNAs were identified in tumours and the tissue levels of seven
microRNAs (miR-21, miR-128, miR-132, miR-134, miR-155, miR-210 and miR-409-5p) appropriately discriminated
oligodendrogliomas from glioblastomas. Genomic, epigenomic and host gene expression studies were conducted to
investigate the mechanisms involved in these deregulations. Another aim of this study was to better understand glioma
physiopathology looking for targets of deregulated microRNAs. We discovered that some targets of these microRNAs such
as STAT3, PTBP1 or SIRT1 are differentially expressed in gliomas consistent with deregulation of microRNA expression.
Moreover, MDH1, the target of several deregulated microRNAs, is repressed in glioblastomas, making an intramitochondrial-
NAD reduction mediated by the mitochondrial aspartate-malate shuttle unlikely. Understanding the connections between
microRNAs and bioenergetic pathways in gliomas may lead to identification of novel therapeutic targets.
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Introduction
Gliomas are brain tumours typed as oligodendrogliomas,
astrocytomas, high-grade astrocytomas (glioblastomas) and sev-
eral other subtypes, which are an important cause of mortality in
adults and children. The original cell type(s) of these tumours is
still uncertain and the molecular determinants of their aggres-
siveness have been the subject of numerous investigations [1].
The incorporation of molecular information would help the
pathologist to discriminate between these tumour types, which
show variable pathology and are known for their heterogeneity.
Molecular analyses are expected to reveal appropriate markers of
gliomas for typing and prognosis. In particular, genome-wide
gene expression profiles were studied to stratify gliomas and to
define the intrinsic features of the subtypes [2,3]. Other attempts
have focused on other transcriptomic markers and were based on
analyses of expression levels of microRNAs in tumour tissues (for
review [4]).
MicroRNAs (miRNAs) are short ,22 nucleotide non-coding
single-stranded RNAs that negatively regulate gene expression by
binding to target mRNAs and, although less frequent, can
stimulate translation of some mRNAs [4].
To date, close to 1100 different human miRNAs are referenced
in the miRBase (release 16; sept 2010). They play a crucial role in
the regulation of processes such as development, differentiation,
cell proliferation and apoptosis, with many of these processes often
altered in tumours (for review [5]). Moreover, miRNAs may be
transferred between glioma cells and adjacent cells through gap
junctions and induce targeted inhibition of protein expression in
the acceptor cells [6] and they also participate in cell to cell
signalling via an exosomal-mediated transfer between cells [7].
In this report, we measured the expression levels of 282 different
miRNAs in tissues from oligodendrogliomas and glioblastomas
that were classified by pathology analyses and on the basis of their
molecular subtyping according to Li , et al. [3]. Specific miRNA
patterns for these two different types of glioma were evidenced and
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20600we addressed two main questions: why are these miRNAs
deregulated in this tumour context? what are the impacts of these
deregulations on cellular pathways?
Materials and Methods
The study was approved by the Biological Resource Center
Ethics Review Board 38043 Hospital of Grenoble. Written
consent was obtained from each patient or family.
Biological samples
Glial tumour samples (12 oligodendrogliomas and 12
glioblastomas) and 4 control brain tissues were obtained at
t h et i m eo fs u r g e r yf r o mp a t i e n t si nG r e n o b l eU n i v e r s i t y
Hospital. Samples were immediately frozen at 280uC. Tissues
came from newly diagnosed tumours that were typed according
to the latest WHO classification (2007) by two neuropatholo-
gists (C. Salon and C. Godfraind). In addition, expression data
of 54 Affymetrix Genechip probe sets were used for typing the
tumour samples according to the gene expression signature-
based classification proposed by Li , et al.[ 3 ] .O l i g o d e n d r o -
gliomas (ODG) and glioblastomas (GBM) in this study were
sorted into the O group and G group, respectively, with a
confidence value higher than 85% compared to the classifiers
of Li , et al. [3]). Tumour samples were also characterised by
the gene expression signature-based classification proposed by
Phillips , et al.[ 2 ] ,s e q u e n c i n go faP C Rf r a g m e n to ft h eIDH1
gene to seek codon 132 mutations [1,8], detection of the 1p19q
LOH [1], as well as other clinical features (supplementary
Table S1).
Human glioblastoma cells (U87 or low passage cell lines) were
cultured in standard DMEM medium supplemented with 10%
fetal bovine serum. The cells were submitted to different O2
concentrations (0.3%, 3% and 20%) for 24 h before harvesting.
RNA extraction
RNAs were extracted from cells or tissue samples using the
mirVana
TM miRNA isolation kit (Ambion). Low-molecular-weight
(LMW) RNAs (,250 bp) were purified and separated from high-
molecular-weight (HMW) RNAs (.250 bp). The LMW and
HMW quality was checked with the RNA Nano 6000 kit on
Bioanalyzer 2100 (Agilent Technologies).
Membrane-array hybridisation and real-time PCR
Hybridisation was analysed using nylon membranes on which
oligonucleotide probes complementary to mature miRNA
sequences (Ambion) were spotted in duplicate. LMW RNAs
(2 mg) were labelled by radioactive poly(A) tailing with 2 mCi of
ATP (a
33P) (PerkinElmer Life) and 2 U of poly(A)polymerase
(Ambion). Labelled RNAs were hybridised to the membranes for
2d a y sa t5 0 uC; then the arrays were washed twice with 5X SSC,
0.5% SDS, and exposed on a phosphor screen for 48 h and
scanned with a BAS 5000 Phosphor scanner (Fujifilm Raytest).
The signals were quantified with Array Gauge 4.0 software
(Fujifilm) and normalised by background subtraction and global
normalisation.
Real-time PCR analyses of LMW RNAs were based on mature
miRNA-specific Taqman
H MicroRNA assays (Applied Biosys-
tems). Ct measurements were taken on a Stratagene Mx3005p
system (Agilent Technologies). RNU24 small nucleolar RNA was
used as an internal normalization reference. The calculations were
made using the Relative Expression Software Tool (REST)
(http://www1.qiagen.com/products/rest2009software.aspx).
mRNA profiling
Gene expression profiles were analysed on GeneChip
H Human
Genome U133 Plus 2.0 (Affymetrix) corresponding to 47,401
unique transcripts. Microarrays were used in accordance with the
manufacturer’s protocol. In brief, 5 mg of HMW RNA was reverse
transcribed to single-stranded cDNA and after second-strand
cDNA synthesis, biotin-labelled antisense cRNA was generated by
in vitro transcription. The cRNA preparation was fragmented and
hybridised to the oligonucleotide microarray and then washed,
stained and scanned. Raw expression data were analysed using
GeneChip Operating software (GCOS) version 1.2 (Affymetrix)
and Robust Multi-array Average (RMA) analysis.
CpG mapping and DNA methylation analysis
CpG islands were sought in the 2000-bp region upstream of the
miRNA gene transcription start sites previously described by
Marson , et al. [9] using Methyl Primer Express v1.0 software
(Applied Biosystems) or as described for miR-124-2, miR-127 and
miR-128 [10–12].
Genomic DNA extracted using standard protocols (Qiagen) was
treated with sodium bisulfite using the EZ DNA methylation-Gold
kit according to the manufacturer’s protocol (Zymo Research).
Amplification by PCR and pyrosequencing (primer list, supple-
mentary Table S2) were performed and the methylation rate at
each CpG position was calculated (PyroMark ID Biotage
QIAGEN).
Western blot analysis
Tissues were lysed using Promega lysis buffer including protease
inhibitors. Western blots were performed with PVDF membranes.
Antibodies were from Santa Cruz Biotechnology (BCL2, SNAP25,
THBS1, MDM2, SIRT1, anti-mouse and anti-rabbit horseradish
peroxidase-conjugated secondary antibodies); Abcam (CD44,
MDH1, STAT3, Y705P-STAT3, CCPG1, PTBP1) or Neomar-
kers (beta-actin). Signals were detected by chemiluminescent
detection (ECL, Amersham Biosciences) and protein amounts
were normalised to the beta actin signals. Images were processed
with ImageJ software (http://rsbweb.nih.gov/ij/).
Data analysis, statistics, database
The results are shown as the mean of at least triplicate
individual measurements. Statistical significance was assessed
using the two-tailed t-test as well as ANOVA as appropriate. P-
values less than 0.05 were considered statistically significant. We
used a threefold expression difference as a cutoff level. We used the
Sanger database (http://www.ebi.ac.uk/enright-srv/microcosm/
htdocs/targets/v5/) to identify relevant miRNA targets. Pathway
rationalisation was performed with Ingenuity Pathway Analysis.
Results
miRNA contents in glioma tissues
Brain tumour and control tissues were analysed for miRNA
contents using two different techniques, hybridisation onto
membrane arrays and real-time PCR. A total of 282 different
miRNAs were measured in the samples (supplementary Table S3).
The results were expressed as the ratios, for every single
miRNA, of their average amounts measured in gliomas (glioblas-
toma [GBM] or oligodendroglioma [ODG]) to their amounts in
control samples. MiRNAs with ratios higher than 3 or lower than
0.33 (either GBM to control or ODG to control) obtained by any
of the two methods were considered glioma markers and retained
for further analysis.
miRNA in Glial Tumours
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listed in Table 1. Eighteen of these 26 miRNAs were detected by
both methods. Most of the time, over- or under-expression of
miRNAs in the gliomas compared to the control tissue,
respectively, was consistently detected with both techniques. We
assumed that discrepancies were related to the fact that the
dynamic range of the recorded hybridisation signals seemed to be
shrunken in comparison to that of the PCR measurements.
Fourteen miRNAs had high glioma to control ratios and 11
had low ratios. Only miR-210 was found in higher amounts in
GBM but in lower amounts in ODG than in control tissue. The
results obtained by real-time PCR were plotted on a graph that
displays the ODG to control tissue miRNA ratios versus the
GBM to control tissue miRNA ratios (Fig. 1). This shows that
there are obviously two common sets of miRNAs that are either
over-expressed or under-expressed in gliomas in comparison to
the control brain tissue. In addition, six miRNAs are over-
expressed in GBM compared to ODG (GBM to ODG miRNA
ratios above 3 in miR-21, miR-13 2 ,m i R - 1 3 4 ,m i R - 1 5 5 ,m i R -
210 and miR-409-5p). On the contrary, a higher level of
expression of miR-128 was found in ODG than in GBM
(Table 1).
Coding region structures and miRNA expression
Alterations of the genome structure such as losses of
heterozygosity, gene amplifications or changes in the miRNA
sequences (SNPs or mutations that can interfere with the assays)
may lead to variations of the total amount of assayed miRNAs.
Genomic analyses were carried out to assess the copy number
o ft h em i R N Al o c ii nt h et i s s u es a m p l e sb yP C R( p r i m e r si n
supplementary Table S4). We specifically focused our attention
on the miRNAs with low levels in gliomas (miR-7, miR-124,
miR-127-3p, miR-128, miR-134, miR-139-5p, miR-149, miR-
339-5p and miR-409-5p) and on three over-expressed miRNAs
(miR-9, miR-21 and miR-155). For miR-128 which is encoded
by two different loci and miR-7, miR-9 and miR-124 by three
different loci, the copy numbers of all the loci were analysed.
However, we were unable to amplify the miR-124-3 locus.
No deletion or gene amplification was found in the tumour
tissues for the studied coding regions (supplementary Fig. S1).
Using the Affymetrix SNP6.0 arrays, we noted that a 7p22.3
fragment (bp 52,899 to 1,466,894), which contains the miR-339
coding region, was present in triplicate copies in GBM. All PCR
fragments were sequenced and proved free of mutation.
Expression levels of the miRNA hosting genes
In a number of cases, miRNAs are hosted in the structure of
coding or non-coding transcribed genes and some of them are
co-expressed with their host genes in normal tissues [13]. Any
correlation between host-gene transcript levels and miRNA
Table 1. Deregulated miRNAs in gliomas versus control brain
tissue.
Real-time PCR Membrane-array
miRNA GBM/N ODG/N
GBM/
ODG GBM/N ODG/N
GBM/
ODG
miR-21 87.8
{ 9.0 9.8 4.8 1.3 3.7
miR-155 34.5 3.1 11.2 4.8 0.6 8.4
let-7f 23.2 25.8 0.9 10.6 5.2 2.0
let-7a 19.2 20.5 0.9 4.1 4 1.0
miR-17 12.9 17.9 0.7 ND ND ND
miR-16 11.4 5.0 2.3 4.5 2.7 1.7
miR-26b 9.0 7.1 1.3 ND ND ND
miR-374a 7.8 7.4 1.0 ND ND ND
miR-126 4.8* 2.8 1.7 ND ND ND
let-7d 4.2 3.0 1.4 1.6 2.3 0.7
miR-20a 3.6 5.0 0.7 ND ND ND
miR-15b 3.3 3.4 1.0 4.3 1.2 3.7
let-7b 3.3 3.4 1.0 1.3 1.8 0.7
miR-9 2.1 5.7 0.4 2.1 3.5 0.6
miR-210 2.3 0.29 8.1 5.6 0.5 10.7
miR-409-5p 0.32
{ 0.07 4.6 ND ND ND
miR-132 0.28* 0.09 3.2 0.5 0.28 1.8
miR-134 0.20 0.04 5.8 2.7 0.19 14.2
miR-149 0.18* 0.10 1.8 ND ND ND
miR-128 0.12 0.46 0.26 0.29 0.33 0.9
miR-7 0.11 0.09 1.2 0.15 0.15 1.0
miR-330-3p 0.08 0.05 1.7 0.25 0.32 0.8
miR-139-5p 0.07 0.09 0.8 0.13 0.08 1.6
miR-339-5p 0.07* 0.11 0.6 ND ND ND
miR-127-3p 0.06 0.03 2.0 0.7 0.06 11.9
miR-124 0.00 0.00 1.0 0.2 0.11 1.8
miRNAs were assayed by real-time PCR and hybridisation in glioblastomas
(GBM), oligodendrogliomas (ODG) and control brain tissues (N). miRNA ratios
between the different tissues are reported as indicated. Statistical significance
was assessed using ANOVA. All P-values were lower than 0.05 (and between
0.05 and 0.2 when indicated by *).
{ratios above 3 are in boldface.
{ratios below 0.33 are in italics.
ND: not detected.
doi:10.1371/journal.pone.0020600.t001
Figure 1. Deregulated miRNAs in gliomas. Correlation between
miRNA expression in ODG versus miRNA expression in GBM. Data were
obtained by real-time PCR. ODG/N and GBM/N miRNA ratios are
expressed in log10(ratio value). Triangles: miRNAs with a GBM/ODG ratio
higher than 3 or lower than 0.33. Diagon illustrates identical expression
of miRNAs in glioblastomas and oligodendrogliomas.
doi:10.1371/journal.pone.0020600.g001
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mechanism of miRNA expression control. From Affymetrix
hybridisation experiments we analysed the expression levels of
17 genes corresponding to 15 different mature miRNAs
(Table 2).
For few miRNAs, we noted an apparent correlation between
the changes in expression levels of the host genes and the
respective changes of the mature miRNA amounts in gliomas.
The genes that host two mature miRNAs, present in very low
amounts in gliomas (miR-128 with two gene isoforms and miR-
139-5p), are down-regulated in gliomas. The expression level of
at least one (C19orf30) of the three isoforms that encode miR-7
(miR-7 is expressed at low levels in gliomas) was severely down-
regulated in gliomas. The transcribed MIR155HG gene, which
hosts the over-expressed miR-155 and the SMC4 gene, which
hosts both the miR-15b and miR-16 were found over-expressed
in GBM but not in ODG. In all the other cases host-gene
expression was found to be deregulated in a way that is
inconsistent with the variation of the expression levels of the
hosted miRNAs in the tumours.
Regulation of the expression levels of miRNA by
epigenetic modifications
Expression levels of miRNAs can also be controlled by
epigenetic changes such as methylations of CpG islands in
promoters. We screened the genomic sequences for the presence
of CpG islands in the 2-kbp region upstream of the transcription
start sites and analysed by pyrosequencing eight CpG islands
upstream of the genes that encode seven different miRNAs (Fig. 2).
In GBM the levels of methylation of gene promoter regions was
nearly identical to the levels in control tissues. On the contrary, the
proportion of methylated CpGs in promoters of miR-210 and
miR-330 was found significantly higher in ODG than in GBM
and control tissue (57.7; 14.6 and 14.4 for miR-210, and 65.3; 22.6
and 26.6 for miR-330 in ODG, GBM and control tissue,
respectively).
Effect of hypoxia on miRNA gene expression
Since it is known that hypoxia can settle in gliomas, we checked
whether extrinsic parameters such as oxygen concentration could
affect the expression level of some miRNAs in tumour cells
Table 2. miRNA host gene expression in gliomas.
Expression level
GBM/N ODG/N
Host genes
1
Host genes micro RNAs Host genes micro RNAs
miRNA loci
{ Symbol Name Gene location
Coregulated hostgene and miRNA
miR-128-1 R3HDM1 R3H domain containing 1 2q21.3 0.2* 0.1 0.3 0.5
miR-128-2 ARPP-21 cyclic AMP-regulated phosphoprotein 21 kD 3p22.3 0.1 0.1 0.7 0.5
miR-139 PDE2A phosphodiesterase 2A. cGMP-stimulated 11q13.4 0.1 0.1 0.3 0.1
miR-7-3 C19orf30 chromosome 19 open reading frame 30 19p13.3 0.1 0.2 0.2 0.1
Poorly coregulated hostgene and miRNA
miR-155 MIR155HG MIR155 host gene (non-protein coding) 21q21.3 5.9
{ 34.5 0.7 3.1
miR-15b SMC4 structural maintenance of chromosome 4 3q26.1 4.8 3.3 1.8 3.4
miR-16-2 SMC4 3q26.1 4.8 11.4 1.8 5.0
miR-149 GPC1 glypican 1 2q37.3 2.8 0.2 0.9 0.1
miR-17 MIR17HG MIR17 host gene (non-protein coding) 13q31.3 1.4 12.9 2.9 17.9
miR-20a MIR17HG MIR17 host gene (non-protein coding) 13q31.3 1.4 3.6 2.9 5
miR-26b CTDSP1 CTD (carboxy-terminal domain, RNA polymerase
II, polypeptide A) small phosphatase 1
2q35 1.4 9.0 1.6 7.1
miR-339 C7orf50 chromosome 7 open reading frame 50 7p22.3 1.2 0.1 0.9 0.1
miR-9-2 LOC645323 5q14.3 1.1 2.1 3.0 5.7
miR-16-1 DLEU2 deleted in lymphocytic leukemia 2 (non-protein
coding)
13q14.2 1.0 11.4 0.9 5.0
miR-7-1 HNRNPK heterogeneous nuclear ribonucleoprotein K 9q21.32 1.0 0.2 1.0 0.1
let-7f-2 HUWE1 HECT, UBA and WWE domain containing 1 Xp11.22 0.8 23.2 0.8 25.8
miR-126 EGFL7 EGF-like-domain. multiple 7 9q34.3 0.7 4.8 0.6 2.8
miR-330 EML2 echinoderm microtubule associated protein
like 2
19q13.32 0.7 0.1 0.6 0.1
miR-9-1 C1orf61 chromosome 1 open reading frame 61 1q22 0.5 2.1 1.7 5.7
Host gene expression levels in gliomas were assessed by Affymetrix genechip hybridisation and normalized to the expression levels in control brain tissue. The
expression levels of the mature miRNAs measured by real-time PCR (Table 1) are reported.
*ratios below 0.33 are in italics.
{ratios above 3 are in boldface.
{miRNA loci corresponding to miRNAs that showed coexpression with their host genes in normal tissue as reported [13] are underlined.
1The 17 reported genes and transcribed regions host 19 different miRNA loci that code for 15 mature miRNAs.
doi:10.1371/journal.pone.0020600.t002
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different oxygen concentrations (20%, 3% and 0.3%) and the
cellular miRNA contents were assessed. The expression of miR-
15b, miR-16, miR-17, miR-20a, miR-210, let-7a, let-7b, let-7d
and let-7f was found to be increased by hypoxia (the ratios miRNA
levels at 0.3% O2 / miRNA level at 20% O2 ranged between 1.5
and 2.9). Oxygen concentration-dependent deregulation of the
expression of miR-210 is shown in supplementary Fig. S2. On the
contrary, for example, miR-100 expression was found to be
unaffected by low oxygen concentration, suggesting that the
expression of only a restricted set of miRNAs is regulated by the
oxygen concentration. As a control, in the U87 glioma cells we
also measured the overexpression of the CA9 (carbonic anhydrase
IX), HIG2 (hypoxia-inducible gene-2) and LOX (lysyl oxidase)
genes that have been reported to be overexpressed by hypoxia
[14]. This confirmed that the U87 cells duly responded to our
experimentally imposed oxygen deprivation.
Target analysis
Several targets of the 26 glioma-specific miRNAs were selected
and nine of them were studied because the amounts of the target
proteins in tumour or control brain tissue lysates were found at a
detectable level when assessed using Western blot (Fig. 3A).
Detection of CD44 was also included because it has been found to
be involved in miR-21 production [15] and in STAT3 activation
[16].
Low amounts of SNAP25 and THBS1 were noted in ODG.
High levels of STAT3, CCPG1 and CD44 but an undetectable
amount of MDH1 were found in GBM (supplementary Fig. S3).
The level of SIRT1 was low, while high amounts of BCL2,
MDM2 and PTBP1 were noted in both types of tumours (Fig. 3A
and Table 3). In addition, we also detected the Y705 phosphor-
ylated form of STAT3 and found increased amounts of this
phosphorylated form of STAT3 in GBM in comparison to non-
tumour tissue and ODG (supplementary Fig. S4).
The targets can then be classified into two main groups
(Table 3). One group corresponds to proteins that show changes in
their tissue concentrations that grossly correlate with the mRNA
levels (SNAP25, STAT3 and CD44). In the second group, the
modification of the protein levels between tumours and control
tissue poorly correlates with the mRNA level changes. For
example, lower amounts than expected regarding mRNA levels
are noted for MDH1 in GBM and SIRT1 in gliomas; or the
protein concentration was increased in glioma tissues, although the
mRNA was only slightly modified (typically CCPG1, BCL2,
MDM2 and PTBP1). In this group, a modified concentration of
specific miRNAs may be one of the possible events that controls
the levels of proteins encoded by these genes.
Discussion
miRNAs for molecular phenotyping of gliomas
This analysis focused on an original comparison of two distinct
groups of gliomas and was performed by two different technical
and complementary approaches. With the choice of a cut-off set to
$3-fold differential expression of the miRNAs between the
samples, we were able to identify 26 miRNAs that appeared to
be deregulated in glioma samples in comparison to control brain
samples. Strikingly, the expression levels of most of the miRNAs
identified were found to be very similar in the two types of tumour
sample (Fig. 1). This suggests that a number of pathways for the
regulation of the expression of several miRNAs are shared by
ODG and GBM. Nevertheless, we found six miRNAs that showed
more than three times the expression in the GBM group than in
the ODG group of tumours. On the contrary, only one miRNA
appeared more than three times overexpressed in ODG than in
GBM. Accordingly, a set of seven markers of interest are described
– miR-21, miR-128, miR-132, miR-134, miR-155, miR-210 and
miR-409-5p – which clearly distinguishes the two groups of
tumours.
As a consequence, this study has several implications for the
pathology gliomas. A clear distinction between glioblastomas and
low-grade tumours can be made feasible by molecular analyses
based not only on mRNAs (as described for example in [2,3]) but
also on miARN measurements (supplementary Table S1). In the
latter case, a small number of miRNA markers might be sufficient
to distinguish GBM and ODG. This may indicate that appropriate
RT-PCR assays or in situ hybridization using miRNA-targeting
probes, performed in conjunction with conventional assays, may
be of value in identification of glioma subtypes. Nevertheless, the
specific miRNAs identified in this study are not yet sufficient alone
to allow the distinction between low-grade tumour subtypes that
are distinguished by the 1p and 19q LOH status.
miRNA contents in gliomas have already been analysed by
several laboratories, but most of these analyses were done on
astrocytomas and/or GBM, and few data have been reported on
ODG (supplementary Table S5). Large-scale analyses that focus
on glioma miRNA content and comparison between GBM and
ODG are not sufficiently documented. In this study, we identified
six miRNAs that, to the best of our knowledge, have never been
reported as deregulated in gliomas in comparison to control brain
tissue (let-7a, let-7b, let-7f and miR-374a, which are over-
expressed in gliomas; miR-339-5p and miR-409-5p, which are
under-expressed in gliomas). For 14 miRNAs in GBM, there is a
Figure 2. Methylation levels of CpG islands located upstream
of the transcriptional starts of miRNA coding regions. Promoter
regions of seven different miRNA genes were analyzed for the presence
of CpG islands and for their methylation level. DNA fragments amplified
from CpG islands were analyzed by pyrosequencing as described in
Materials and Methods. Two different CpG islands were investigated for
miR-339 coding region upstream transcription start sites, TSS1 and
TSS2. Methylation levels are reported as ratios between gliomas (GBM
or ODG) versus control brain tissue (left y-axis). Black bars: GBM/N ratios;
white bars: ODG/N ratios. GBM to ODG miRNA expression levels are
reported in open triangles (right y-axis).
doi:10.1371/journal.pone.0020600.g002
miRNA in Glial Tumours
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(supplementary Table S5). Six miRNAs (miR-15b, miR-17, miR
20a, miR 21, miR 155 and miR 210) were found to be up-
regulated, while eight others (miR-7, miR-127-3p, miR-128, miR-
132, miR-134, miR-139-5p, miR-149 and miR-330-3p) were
generally measured in low amounts in tumours. There is broad
Figure 3. Immunodetection of target proteins and synopsis of their roles in cellular pathways and interactions with miRNAs. A,
tissular lysates from control brain samples, ODGs and GBMs were analyzed by western blot with antibodies directed against the proteins indicated on
the left. Equal quantities of proteins loaded on the gel were ascertained by immunodetection of beta-actin. A full length blot for detection of MDH1 is
presented in supplementary Fig. S3. B, network with miRNAs and proteins. Protein names: see Table 3; EP300: E1A binding protein p300; STAT3 Ac:
acetylated form of STAT3; IL6: interleukin 6; HIF-1a: hypoxia inducible factor-1alpha.
doi:10.1371/journal.pone.0020600.g003
Table 3. Expression levels of immunodetected proteins and their encoding mRNAs.
Deregulated miRNAs targeting protein-coding
mRNAs
GBM/N ODG/N Upregulated Downregulated
mRNA Protein mRNA Protein
Moderate correlation between protein amounts and mRNA levels
SNAP25 synaptosomal-associated
protein 25kDa
0.0* 0.6 0.1 0.2 miR-16
STAT3 signal transducer and
activator of transcription 3
2.8 5.0 1.0 0.9 miR-17, miR-20a
CD44 CD44 molecule (Indian
blood group)
18.0
{ ‘ 1.8 1
{
Poor correlation between protein amounts and mRNA levels
MDH1 malate dehydrogenase 1,
NAD (soluble)
0.3 0 0.3 0.3 miR-15b, miR-16, miR-26b,
miR126
SIRT1 sirtuin 1 0.5 0 1.5 0 miR-132
CCPG1 cell cycle progression 1 0.9 ‘ 1.0 1
{ miR-21, miR-155, miR-374a miR-139-5p
BCL2 B-cell CLL/lymphoma 2 0.7 3.5 0.9 3.3 miR-15b, miR-17 miR-139-5p
MDM2 Mdm2 p53 binding protein
homolog (mouse)
1.7 8.3 0.8 3.0 let-7b, let-7f miR-339-5p
PTBP1 polypyrimidine tract binding
protein 1
3.2 ‘ 1.1 ‘ miR-124, miR-339-5p, miR-149
THBS1 thrombospondin 1 3.6 1.1 0.5 0.2 miR-21
mRNA expression levels (from Affymetrix genechip hybridisation) and protein levels (from Western blots; Fig. 3) are given as the ratios between gliomas and control
tissue. Up-regulated or down-regulated potential targeting miRNAs are indicated.
*ratios below 0.33 are in italics.
{ratios above 3 are in boldface.
{undetectable levels in control and ODG.
‘undetectable levels in control samples.
doi:10.1371/journal.pone.0020600.t003
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21 and the under-expression of miR-7, miR-128 and miR-139-5p
in gliomas. However, several discrepancies in all the published
data can be found for let-7d, miR-9, miR-16, miR-26b, miR-124
and miR-126 (supplementary Table S5). Divergent results may be
related to the heterogeneous nature of the tumour samples
themselves used in the studies (tumour tissues or cultured cell
lines), and most probably to the methodological approaches. In the
present study, miRNAs were measured using two different
methods. However, while the real-time PCR measurements
strictly assay only one mature form of every single miRNA,
hybridisation arrays may detect undetermined additional forms of
miRNA with longer or end-frayed sequences in comparison to the
mature miRNA form. In addition, using different RNAs to
standardise the measurements in the different studies (let 7a or
RNU6B or RNU24) might have a considerable influence on the
final results.
Variations in the amounts of miRNA measured may indicate
true tissue-dependent deregulations of the miRNA gene expression
levels. However, other molecular events may interfere with the
miRNA measurements and have adverse effects on these
conclusions. Alterations in the mature miRNA sequences
(mutations or SNPs), a potentially very critical problem in terms
of reliability of the hybridisation or PCR-based assays of such
small RNA components, may lead to apparently reduced amounts
of detectable miRNAs. Variations may also be related to
modifications of the copy number of miRNA genes, the activity
of their corresponding promoters, or the post-transcriptional
processing of the miRNAs. Finally, the miRNA expression levels
may be dependent on the cellular type composition of the tumour
samples themselves.
Gene structure and copy number modifications
inadequately explain the expression level of miRNA in
gliomas
The copy numbers of the miR-7-1, miR-7-2, miR-7-3, miR-
124-1, miR-124-2, miR-127, miR-128-1, miR-128-2, mirR134,
miR-139, miR-149 and miR-409 genomic loci were found to be
unaffected in the glioma samples and the sequences of all these
miRNA genomic loci were found to be identical to the reference
sequences (Supplementary Fig. S1). Therefore, it can be concluded
that in comparison to the control brain samples, reduced
expression of the corresponding miRNAs in tumour samples does
not stem from gene deletions, mutations or SNPs. Similarly, no
gene copy number modifications seem to be responsible for the
high expression of mature miR-9, miR-21 and miR-155.
Consequently, for miR-21, miR-128, miR-134, miR-155 and
miR-409-5p, which are differentially expressed in GBM and
ODG, no change in gene copy number was found to support the
substantial difference in expression levels in the two different types
of tumour.
However, we found three copies of the 7p22 genomic region
that encodes miR-339 in GBM. The overall expression of this
miRNA was found to be lower in gliomas than in the control brain
tissue. It was therefore hypothesised that transcriptional or post-
transcriptional events may impact the expression level of this
particular miRNA.
Expression control, post-transcriptional regulation and
environmental effect
A high correlation in control brain tissues between the
expression of miRNAs and their host genes was previously
identified in miR-7-3, miR-9-1, miR-126, miR-128-1 and miR-
139-5p [13]. We drew a similar conclusion for miR-7-3, miR-128-
1, miR-128-2 and miR-139-5p but not for miR-9-1 and miR-126
in gliomas (Table 2). We can conclude that at least in miR-126, a
co-regulated expression with EGFL7 appears to be disrupted in
gliomas. A similar observation was also previously reported in the
case of the human colon cancer [17].
Several miRNA coding regions are clustered in the genome. For
example, miR-16, which was found to be over-expressed in both
types of glioma, is encoded by the miR-16-1 gene that is clustered
with miR-15a on chromosome 13q14.2 and by the miR-16-2 gene
clustered with miR-15b on chromosome 3q25.33. Since we
detected over-expression of miR-15b and no change in the miR-
15a expression level in the two types of glioma, it can be concluded
that only the miR-15b/miR-16-2 cluster is deregulated in these
tumours. Another cluster, also dubbed oncomir-1, with the co-
transcribed miR-17, miR-18, miR-19, miR-20a and miR-92
genes, is located on chromosome 13q31.3 [18]. It is over-expressed
in gliomas, as shown by the high amounts of the mature forms of
miR-17 and miR-20a. The absence of detection of the other
members of the cluster might be the consequence of as yet not well
defined post-transcriptional events. Stability of the precursors or
mature miRNAs is probably controlled by processes that may
affect the steady-state amounts of tumour miRNAs as well as the
half-life of specific segments of the precursor transcripts (exempli-
fied for miR-138 [19]). This also seems to hold true for miR-149,
miR-330-3p and miR-339-5p, for example, since the amounts of
these mature miRNAs were very low, whereas the expression level
of the host gene transcript was nearly unaffected in gliomas
compared to control brain tissue. All these observations suggest
that the maturation process of miRNA transcripts and its
deregulation remain to be investigated for all the individual
miRNAs.
Epigenetic regulation of miRNA gene expression is also
expected and has been reported to occur through methylation of
CpG islands for miR-124 [10], miR-127 [11] and miR-128 [12],
for example. In miR-124-2, miR-127, miR-128, miR-155 and
miR-339 genes, we found that the CpG methylation levels in
gliomas were nearly identical compared to control tissues.
However, we found that upstream of the miR-210 and miR-330
genes the CpG methylation rates were higher in ODG than in
GBM (Fig. 2). Higher expression of miR-210 in GBM than in
ODG may therefore be related to the increased methylation rate
for miR-210 in ODG, but a similar explanation for miR155 seems
unlikely.
Finally, we found a number of genes that can be up-regulated in
GBM cells in vitro by environmental conditions such as hypoxia.
This is the case for miR-210, in agreement with previous studies
that showed that miR-210 is over-expressed in low oxygen
concentration in breast cancer or colon cancer cell lines [20,21].
Interestingly, it can be hypothesised that in GBM, hypoxia may
favour the increase of miR-210 concentration, whereas in ODG,
excess promoter methylation may reduce expression of this
miRNA.
Tissue-specific miRNAs
miR-9, miR-124, miR-128, miR-132, miR-134 and miR-409-
5p are known as brain-enriched or even brain-specific miRNAs
(for review [22,23]). In the rat, miR-9 is down-regulated during
oligodendrocyte differentiation from oligodendrocyte progenitor
cells [24]. A high amount of this miRNA in ODG might therefore
be linked to a dedifferenciation process during tumorigenesis.
Tissue-specific expression of some miRNAs may lead to
apparent over- or under-expression of these miRNAs in tumour
tissues. For example, miR-124 is constitutively expressed in mature
miRNA in Glial Tumours
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20600neurons [25]. It promotes neurite outgrowth during neuronal
differentiation, possibly by regulation of the cytoskeleton [26].
miR-124 is the most abundant miRNA in the adult mammalian
brain, accounting for 25%–48% of all brain miRNAs [27]. It was
detected in lower amounts in anaplastic astrocytomas and
glioblastomas than in non-neoplastic brain tissue [28]. miR-124
targets the mRNA that encodes PTBP1 (PTB/hnRNP I), a global
repressor of alternative pre-mRNA splicing in non-neuronal cells
[29].
miR-128 is more strongly expressed in neurons than in
astrocytes [30]. miR-132 is enriched in neurons and is involved
in neurite outgrowth [31]. Finally, miR-134 is present in dendrites,
where it modulates the development of dendritic spines, neuronal
protrusions that connect with other neurons and control neuronal
transmission and plasticity [32,33]. miR-134 and miR-409-5p
genes are located in a very large cluster of brain-specific miRNAs
at chromosome 14q32.31, as recently reported [23].
The low levels of miR-124, miR-128, miR-132, miR-134 and
miR-409-5p observed in glioma tissues in this study therefore
appears consistent with the fact that the tumour samples
investigated were devoid of normal brain cellular components
that express those miRNAs. There is general agreement that miR-
128, miR-132 and miR-134 are detected in low amounts in
gliomas (supplementary Table S5). It has also been reported that
the members of the let-7 family, miR-21, miR-126, miR-221, and
miR-222 are highly expressed in endothelial cells [34]. As a
consequence, high levels of some of these miRNAs may be related
to substantial vascularization in these tumours. However, in
agreement with others [28], we did not find over-expression of
mir-221 in gliomas.
Functional rationale for miRNA deregulation in gliomas
The expected functional effects of a number of deregulated
miRNAs in gliomas has been reviewed in the literature [4,35–40].
Functional miRNAs have also been identified by integrative
genome analysis or studies of the RISC-specific miRNA/mRNA
profiles [41,42]. However, a comprehensive understanding of the
miRNA roles remains to be established. We described a non-
exhaustive network that can illustrate the possible impacts on
glioma cell pathways of some of the miRNAs found to be
deregulated in this study (Fig. 3B). It is consistent that miR-124,
miR-149 and miR-339-5p, three miRNAs that target PTBP1, a
protein that was found in high amounts in gliomas, were down-
regulated. PTBP1 has recently been reported to play a significant
role in glioblastoma cell proliferation [43].
While this study was in progress, Malzkorn , et al. [44] also
identified that the miR-17-92 cluster is over-expressed in
glioblastomas. The miR-17-92 can down-regulate the expression
of the proapoptotic protein Bim, an event that is related
downstream to the over-expression of BCL2 [45]. Both the high
levels of miR-17 and miR-20a and the low level of miR-139-5p
that putatively target BCL2 are therefore consistent with the high
level of BCL2 we observed in gliomas and are related to an
expected antiapoptotic effect. miR-15b has also been reported to
target BCL2 [46]. However, according to our results, the impact of
the up-regulation of miR-15b on the expression of BCL2 seems to
be less pronounced in gliomas. Antiangiogenic thrombospondin 1
(THBS1) is the target of miR-17-92 [47] and let-7f [34], which are
all overexpressed in gliomas.
In addition, the expression of the miR-17-92 cluster was
recently found to be positively controlled by STAT3 (signal
transducer and activator of transcription 3) [48] and STAT3
expression is controlled by miR-17-92 [49]. Moreover, the
expression of HIF-1a is presumed to be negatively controlled by
miR17 / miR20a [50]. IL-6, whose production is stimulated by
hypoxia and elevated in glioblastoma cells, stimulates the
activation of the transcription factor STAT3. This is consistent
with the increased amount of Y705-phosphorylated form of
STAT3 observed in GBM. In glioblastomas, the higher the
number of Y705P-STAT3-positive tumour cells, the poorer the
outcome is, as reported by Birner , et al. [51]. Once activated,
STAT3 favours the stabilisation of HIF-1a [52] that induces miR-
210 overexpression [21]. In malignant human cholangiocytes,
over-expression of IL-6 was described to up-regulate the
expression of let-7-a, which in turn contributes to the increased
phosphorylation of STAT3 [53]. This may be relevant to the well-
known fact that elevated IL-6 ligand as well as receptor expression
are associated with poor survival of patients with glioma [54].
STAT3 activation by acetylation is a process that requires
CD44 and the active acetyl transferase (EP300: E1A binding
protein p300) [16]. Since we evidenced in glioblastomas that the
amounts of CD44 are high and that the amount of SIRT1 that
inactivates EP300 is low, we can assume that this situation may
facilitate activation of STAT3 by acetylation. All the above data
make STAT3 an important factor in the physiopathology of
glioma cells, in agreement with a recent report [55].
In the cytosol, SIRT1 also deacetylates and activates acetyl-CoA
synthetase (ACSS2) in the presence of oxidised NAD (Fig. 4). As a
consequence of the absence of SIRT1 in gliomas, ACSS2-
dependent production of acetyl-CoA from acetate will be aborted.
Acetyl-CoA, an important metabolite for cell energy and a
precursor at the cross-roads of several metabolic pathways, can
also be produced, at least in adipose tissue, as an end-product of a
pathway that starts by transamination between pyruvate and
glutamate [56] (Fig. 4). In this pathway, IDH1, the cytosolic form
of isocitrate dehydrogenase, produces isocitrate from alpha-
ketoglutarate. In addition, oxaloacetate – a substrate of MDH1
– is co-produced with acetyl-CoA. If this glutamate-dependent
acetyl-CoA generation pathway functions in glial cells, in gliomas
the mutations of IDH1 or the low amounts of MDH1 are expected
to reduce the concomitant production of acetyl-CoA and
oxaloacetate through this pathway.
In fact, in oligodendrogliomas and secondary glioblastomas,
mutations in the IDH1 gene that inactivate the IDH1 catalytic
activity have been reported [8]. IDH1 mutations cause a gain of
function, resulting in the production and accumulation of
oncogenic 2-hydroxyglutarate [57]. In the present study, we
evidenced that MDH1 was nearly undetectable by Western blot in
our glioblastoma lysates. miR-15b, miR-16, miR-26b and miR-
126, all four miRNAs that we found over-expressed in gliomas,
putatively target MDH1 and may contribute to its down-
regulation.
Mutations in IDH1 probably affect the cytosolic pool of alpha-
ketoglutarate, one of the metabolites that fuels the mitochondrial
aspartate-malate shuttle (Fig. 4). The malate-aspartate shuttle
allows cytosolic oxidation of NADH and concomitant reduction of
mitochondrial NADH. MDH1 is the extra-mitochondrial form of
malate dehydrogenase and plays a crucial role in the malate-
aspartate shuttle. The absence of MDH1 prevents this shuttle from
functioning. Interestingly, another critical impact on the mito-
chondrial oxidative phosphorylation system resulting from the
repression of the iron-sulfur cluster assembly proteins by a high
level of miR-210 was recently reported [58]. The control of the
energy metabolism in tumours by miRNAs may contribute to the
aggressive phenotypes of the tumours [59,60].
In addition, in a normal cell context, it was described that
nuclear translocation and activation of p53 are promoted by
MDH1 and hampered by MDM2 [61]. Thus, both the absence of
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20600MDH1 and the over-expression of MDM2, which we showed in
glioblastomas, may negatively control p53 activation and then
enhance tumor formation and growth.
In conclusion, modified amounts of active SIRT1, IDH1 and
MDH1 in gliomas may interfere with acetyl-CoA production. This
may have important consequences that have yet to be understood
on energy production and anabolism in gliomas. The absence of
MDH1 in primary glioblastomas may dramatically impair the
mitochondrialNADreductionthroughthe aspartate-malateshuttle.
Finally, it can be concluded that current limited knowledge on
miRNA targets makes it difficult to anticipate the impact of
miRNA deregulations in tumour tissues. Large-scale analysis as
initiated by others [62–64] is required to obtain more details on
the intricate networks between mRNA, miRNA and proteins.
Supporting Information
Figure S1 miRNA gene copy numbers in gliomas. Genomic
DNA from cells or tissues was extracted using standard protocols
(Qiagen) and was used to assess gene copy number variations
between tissues by three different technical approaches. Method 1:
PCR products obtained with primers listed in supplementary
Table S4 and with two different amounts of purified DNAs for
each sample were run in agarose gels, stained by ethidium
bromide and pictured with the ChemiDoc system and Image Lab
software (BioRad). All signal intensities were normalised with beta
actin PCR product amplified from the same samples. The ratios
between the normalised amount of a gene fragment in gliomas and
the amount of the equivalent fragment in control samples were
calculated. Method 2: real-time PCR with SYBR-green was used to
quantify gene copy number of mir-9-3, miR-124-1. Four different
amounts of DNA were used for each sample. Method 3:
hybridisation on Affymetrix SNP-6.0 arrays. Gene copy number
was analysed in glioblastoma low-passage cell lines using
Affymetrix SNP-6.0 arrays (according to the manufacturer’s
instructions). The quality control assessment for the SNP-6.0
arrays was performed using three parameters: the Contrast
Quality Control (CQC) greater than 0.4, the call rate control
over 86% and the Median of the Absolute values of all Pairwise
Differences (MAPD) less than 0.4. Virtual karyotypes were
generated using Affymetrix Genotyping Console software 3.0
using the reference file created from HapMap samples. This
approach only revealed a modified copy number in the miR-339
coding region (7p22.3 fragment bp 52,899 to 1,466,894). The
ratios between the normalised amount of a gene fragment and the
amount of the equivalent fragment in control samples were
calculated and reported in the figure. Black bars: GBM/N ratios;
white bars: ODG/N ratios.
(TIF)
Figure S2 Effect of oxygen concentration on miRNA and gene
expressions in cultured U87 glioblastoma cells. Cultured cells were
submitted to different oxygen concentrations (20%, 3% and 0.3%).
A, Cellular miRNA contents of miR-100 (diamonds) and miR-210
(squares) were assessed by RT-qPCR. B, mRNA expression levels
of carbonic anhydrase IX (CA9), hypoxia-inducible gene-2
(HIG2), lysyl oxidase (LOX) and GAPDH were measured by
hybridisation to GeneChip
H Human Genome U133 Plus 2.0
(Affymetrix) at three oxygen concentrations: 20% (white bars), 3%
(grey bars) or 0.3% (black bars). All data are reported in arbitrary
units; y-axes are in logarithmic scales.
(TIF)
Figure 4. Metabolic pathways and enzymatic roles of MDH1, IDH1 and SIRT1. ACSS2: acyl-CoA synthetase short-chain family member 2;
IDH1: isocitrate dehydrogenase 1 (NADP+), soluble1; GOT1: glutamic-oxaloacetic transaminase 1; GOT2: glutamic-oxaloacetic transaminase 2; MDH1:
malate dehydrogenase 1, NAD (soluble); MDH2: malate dehydrogenase 2, NAD (mitochondrial); SIRT1: sirtuin 1. Inactivating mutations in IDH1 have
been reported to be frequent in oligodendrogliomas [8].
doi:10.1371/journal.pone.0020600.g004
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20600Figure S3 Full length blot for detection of MDH1 in glioma
samples. Lanes 1 and 2: control; Lanes 3 and 4: ODG; lanes 5 and
6: GBM. Molecular masses in kDa. Experimental conditions as
reported in Materials and Methods and Fig. 3.
(TIF)
Figure S4 Immunodetection of STAT3 and tyrosine705-phos-
phorylated STAT3 in control and tumour samples. Experimental
conditions as reported in Materials and Methods and Fig. 3.
Tissue lysates from control brain samples and tumour samples
(ODG and GBM).
(TIF)
Table S1 Classificationoftheanalysedtumoursamplesaccording
to clinical and analytical parameters. a) Tumours were classified
according to the WHO classification. b) Tumours were typed based
on transcriptomic analyses. mRNA profiles were compared to data
published byLi,etal.[3].Tumourswereclassifiedeitherasgroup O
(corresponding to short survival patients) or G (corresponding to
long-survival patients) according to the coefficient of variation
(indicated as percentage) with the published corresponding tumour
group signatures. c) Tumour typing was based on transcriptomic
analyses. mRNA profiles were compared to data published by
Phillips , et al. [2]. Tumours were classified either as PN (proneural
group, corresponding to low-grade tumours) or MES (mesenchy-
matous group, corresponding to high-grade tumours) according to
the highest coefficient of variation with the published tumour group
signatures. d) The mutation in codon 132 of IDH1 was analysed by
sequencing the corresponding amplified DNA fragment [8]. WT,
wild type. e) Losses of heterozygosity (LOH) at loci 1p and 19q were
analysed by FISH or MLPA [65]. f ) Scoring was calculated on the
following basis: A value of 0 was noted for the following results:
ODGII, O, PN, mutated IDH1, LOH, No hypersignal with
gadolinium, positive response to treatment, and survival period
longer than 36 months, for parameters 1–8 respectively. On the
contrary, a value of 10 was scored for the following results: GBM,
ODGIII or OAII for parameter 1, or G, MES, WT IDH1, no
LOH, hypersignal with gadolinium, no response to treatment,
survival period shorter than 36 months, for parameters 2–8
respectively. The final scoring was assessed using the equation:
((a60)+(b610))/(a+b),whereaisthe totalnumberofparameterswith
a value of 0 and b is the total number of parameters with a value of
10 for each sample. Ideally, low grade tumours should be
characterised by a score of 0 and high grade tumours by a score
of 10.
(XLS)
Table S2 PCR and pyrosequencing primers for DNA methyl-
ation analysis. F: Forward primer; R: Reverse primer; S:
sequencing primer. * 5’ end biotinylated primers. { TSS1,
TSS2: transcription start site 1 and 2, respectively.
(XLS)
Table S3 List of the miRNAs assayed by membrane-array
hybridization and real-time PCR. For miRNA real-time PCR
analysis, LMW RNAs (80 ng) were reverse-transcribed with a
Taqman
H MicroRNA Reverse Transcriptase kit (Applied Biosys-
tems) and Taqman
H microRNA assay containing gene-specific
stem-loop primers. Then the real-time PCR is performed using
Taqman
H PCR Universal Master Mix, No AmpErase
H UNG
(Applied Biosystems) and the Stratagene Mx3005 (Stratagene
Inc.). Five small nucleolar RNAs (RNU6B, RNU19, RNU24,
RNU44 and RNU66) were also assayed by real-time PCR and
RNU24 was determined as the best normaliser by using the
Normfinder algorithm [66]. Individual values were normalised
with the value of RNU24 using Relative Expression Software Tool
(REST) [67].
(XLS)
Table S4 miRNA PCR primers for gene copy number analysis.
F: Forward primer; R: Reverse primer.
(XLS)
Table S5 microRNA expression in gliomas. Data from the
literature. Numbers refer to references indicated below. 1. Ciafre
SA, Galardi S, Mangiola A, Ferracin M, Liu CG , et al. (2005)
Extensive modulation of a set of microRNAs in primary
glioblastoma. Biochem Biophys Res Commun 334 (4): 1351–
1358. 2. Conti A, Aguennouz M, La Torre D, Tomasello C,
Cardali S , et al. (2009) miR-21 and 221 upregulation and miR-
181b downregulation in human grade II-IV astrocytic tumors. J
Neurooncol 93(3): 325–332. 3. Gaur A, Jewell DA, Liang Y,
Ridzon D, Moore JH , et al. (2007) Characterization of microRNA
expression levels and their biological correlates in human cancer
cell lines. Cancer Res 67(6): 2456–2468. 4. Godlewski J, Nowicki
MO, Bronisz A, Williams S, Otsuki A , et al. (2008) Targeting of
the Bmi-1 oncogene/stem cell renewal factor by microRNA-128
inhibits glioma proliferation and self-renewal. Cancer Res 68(22):
9125–9130. 5. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino
N,et al. (2007) A mammalian microRNA expression atlas based
on small RNA library sequencing. Cell 129(7): 1401–1414. 6.
Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N , et al. (2010)
Gliomas display a microRNA expression profile reminiscent of
neural precursor cells. Neuro Oncol 12(5): 422–433. 7. Malzkorn
B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K , et al.
(2009) Identification and Functional Characterization of micro-
RNAs Involved in the Malignant Progression of Gliomas. Brain
Pathol 20(3): 539–550. 8. Nelson PT, Baldwin DA, Kloosterman
WP, Kauppinen S, Plasterk RH , et al. (2006) RAKE and LNA-
ISH reveal microRNA expression and localization in archival
human brain. RNA 12(2): 187–191. 9. Ridzon D, Tan R, Nguyen
J, Broomer A, Caifu C. (2005) MicroRNA Expression Signature in
Human Glioblastoma Multiforme Brain Tumor. http://www3.
appliedbiosystems.com/cms/groups/mcb_ marketing/documents/
generaldocuments/cms_042004.pdf. 10. Silber J, Lim DA, Petritsch
C, Persson AI, Maunakea AK , et al. (2008) miR-124 and miR-137
inhibit proliferation of glioblastoma multiforme cells and induce
differentiation of brain tumor stem cells. BMC Med 6: 14. 11.
Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS , et al. (2009)
Regulation of epidermal growth factor receptor signaling in human
cancer cellsby microRNA-7. JBiolChem284(9):5731–5741. Ref11:
data for ODG.
(XLS)
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